New data from Novo Nordisk’s phase 3 trial of an oral ... in a way that best suits them,” said Professor Filip Knop of Gentofte Hospital, University of Copenhagen, who presented the results ...

In a new study just published in the European Heart Journal, researchers from Herlev and Gentofte Hospital quantify for the first time how life expectancy and cardiovascular disease in people ...

Background Iron deficiency (ID) is common in patients with atrial fibrillation/flutter (AF), but its prognostic implications and optimal diagnostic criteria, particularly in those with and without ...

Funding This work was supported by the Research Council at Herlev-Gentofte Hospital (AHC), the Independent Research Fund Denmark (grant 0134-00363B, AHC), the Novo Nordisk Foundation, Denmark ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

We recently published a list of 12 Best Global Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s dominance over the weight-loss industry. The Danish pharma giant ...

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...

Competition from Him & Hers Health seems to be weighing on Novo Nordisk's stock. A half-hearted rating from Morgan Stanley yesterday isn't cheering investors up very much at all. Yet a new study ...